Compass Therapeutics Inc. (CMPX) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has a promising pipeline and positive analyst ratings, its financials remain weak, and technical indicators suggest a lack of upward momentum. The absence of significant trading signals and recent news further supports a cautious approach.

Technical Analysis

The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 26.231, and moving averages are converging, showing no clear trend. The stock is trading below its pivot level of 6.12, with key support at 5.738 and resistance at 6.502. Overall, the technical indicators do not suggest a strong buy signal.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate bullish sentiment in the options market. However, this is not sufficient to outweigh other factors.

Technical Summary

Sell

Buy

Positive Catalysts

and a promising pipeline, particularly the lead asset Tovecimig, which has met primary endpoints in a Phase III study. Potential commercial launch in 2027 with a $1B peak sales opportunity.

Neutral/Negative Catalysts

Weak financial performance with no revenue, negative net income (-$14.26M), and no gross margin. Technical indicators show bearish momentum, and there is no recent news or significant trading trends to act as a catalyst.

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$14.26M (improved by 36.05% YoY), and an EPS of -0.08. Gross margin dropped to 0%, showing no profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are optimistic with Buy ratings and price targets ranging from $10 to $15. They highlight the company's deep pipeline and the potential success of its lead program, Tovecimig, in treating biliary tract cancer.

8 Analyst Rating

Wall Street analysts forecast CMPX stock price to rise

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.650

Low

Averages

12.67

High

Current: 5.650

Low

Averages

12.67

High

Craig-Hallum

NULL -> Buy

initiated

$15

AI Analysis

2026-02-13

Reason

Craig-Hallum

Price Target

$15

AI Analysis

2026-02-13

initiated

NULL -> Buy

Reason

Craig-Hallum initiated coverage of Compass Therapeutics with a Buy rating and $15 price target.

Craig-Hallum

Buy

initiated

$15

2026-02-13

Reason

Craig-Hallum

Price Target

$15

2026-02-13

initiated

Buy

Reason

As previously reported, Craig-Hallum initiated coverage of Compass Therapeutics with a Buy rating and $15 price target. The firm says Compass has a deep pipeline of next-gen bispecifics targeting angiogenesis and checkpoint inhibition to treat cancer. The company's expertise in developing BsAbs that leverage these synergistic mechanisms of action is shown by lead asset Tovecimig, Craig-Hallum argues, adding that Tovecimig has already met the primary ORR endpoint of a Phase III 2L BTC study and PFS/OS data is expected in March. The firm expects these data to support a potential 2027 commercial launch in 2L biliary tract cancer, where he models a $1B peak sales opportunity. Craig-Hallum also sees significant upside potential in Compass's early-stage pipeline.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CMPX

Unlock Now

CMPX Should I Buy

CMPX Should I Buy

Should You Buy Compass Therapeutics Inc. (CMPX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch